- FDA's decision to lift import alert paves the way for Apotex's oral
solid dose products to be available again for US consumers; Company
moves forward to restore pipeline of shipments to the local market -
To view the Social Media Release, click here: http://smr.newswire.ca/en/apotex-inc/apotex-resumes-shipping-to-the-us
TORONTO, May 11 /CNW/ - Apotex, one of the largest generic
pharmaceutical manufacturers in the world, announced it will soon
resume shipments of its oral solid dose products to the U.S.
market. The announcement comes on the heels of a Food and Drug
Administration (FDA) decision to lift its import alert at Apotex's
largest solid dose manufacturing facility supplying product to the US.
"Apotex is pleased the FDA has recognized the enhancements to our global
quality systems," stated Dr Jeremy B. Desai, Apotex' Chief Operating
Apotex will immediately resume manufacturing and shipping of our solid
dose products into the US market.
Apotex Inc., with 6000 employees in Canada sells to 115 countries a
portfolio of approximately 300 affordable medicines around the globe
and is the largest generic company in the country. It is the top
research and development Canadian corporation in the pharmaceutical
industry with planned expenditures of $2 billion over the next ten
Apotex Corp. is the US Company that markets the products of Apotex, Inc.
Through its sales and marketing headquarters in Weston, Florida and
operations center in Indianapolis, Apotex Corp. is committed to
providing safe and affordable generic medicines.
/NOTE TO EDITORS: Media Assets accompanying this story are available as
SOURCE Apotex Inc.
For further information:
Elie Betito Director Public and Gov't
Tel: (416) 749-9300 Ext. 7366
Cell: (416) 558-5491